76 related articles for article (PubMed ID: 28589759)
1. Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.
Shrestha R; Giri S; Armitage JO; Bhatt VR
Future Oncol; 2017 Jun; 13(14):1239-1246. PubMed ID: 28589759
[TBL] [Abstract][Full Text] [Related]
2. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study.
Hur JY; Choi N; Choi JH; Kim J; Won YW
Thromb Res; 2024 Apr; 236():209-219. PubMed ID: 38461615
[TBL] [Abstract][Full Text] [Related]
3. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.
Noor SJ; Tan W; Wilding GE; Ford LA; Barcos M; Sait SN; Block AW; Thompson JE; Wang ES; Wetzler M
Leuk Res; 2011 May; 35(5):608-13. PubMed ID: 20727590
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
Larsen MK; Skov V; Kjær L; Eickhardt-Dalbøge CS; Knudsen TA; Kristiansen MH; Sørensen AL; Wienecke T; Andersen M; Ottesen JT; Gudmand-Høyer J; Snyder JA; Andersen MP; Torp-Pedersen C; Poulsen HE; Stiehl T; Hasselbalch HC; Ellervik C
Blood Cancer J; 2024 Feb; 14(1):28. PubMed ID: 38331919
[TBL] [Abstract][Full Text] [Related]
5. Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort study.
Svingel LS; Christensen SF; Kjærsgaard A; Stenling A; Paulsson B; Andersen CL; Christiansen CF; Stentoft J; Starklint J; Severinsen MT; Borg Clausen M; Hagemann Hilsøe M; Hasselbalch HC; Frederiksen H; Bak M; Mikkelsen EM
Acta Oncol; 2023 Oct; 62(10):1286-1294. PubMed ID: 37656802
[TBL] [Abstract][Full Text] [Related]
6. Bomedemstat as an investigative treatment for myeloproliferative neoplasms.
Rienhoff HY; Gill H
Expert Opin Investig Drugs; 2023; 32(10):879-886. PubMed ID: 37804041
[TBL] [Abstract][Full Text] [Related]
7. Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan.
Edahiro Y; Ochiai T; Hashimoto Y; Ichii M; Okatani T; Omura H; Nakajima K; Sasaki M; Ando J; Takaku T; Koike M; Izumiyama K; Hiraga J; Yano T; Usuki K; Ohtsuka E; Yokoyama K; Oyake T; Takahashi N; Nishida T; Nakao T; Fukuda Y; Akasaka T; Mugitani A; Ando M; Komatsu N
Hematology; 2024 Dec; 29(1):2340149. PubMed ID: 38626148
[TBL] [Abstract][Full Text] [Related]
8. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.
Barbui T; De Stefano V; Alvarez-Larran A; Iurlo A; Masciulli A; Carobbio A; Ghirardi A; Ferrari A; Cancelli V; Elli EM; Andrade-Campos MM; Kabat MG; Kiladjian JJ; Palandri F; Benevolo G; Garcia-Gutierrez V; Fox ML; Foncillas MA; Morcillo CM; Rumi E; Osorio S; Papadopoulos P; Bonifacio M; Cervantes KSQ; Serrano MS; Carreno-Tarragona G; Sobas MA; Lunghi F; Patriarca A; Elorza BN; Angona A; Mazo EM; Koschmieder S; Carli G; Cuevas B; Hernandez-Boluda JC; Abadia EL; Cirici BX; Guglielmelli P; Garrote M; Cattaneo D; Daffini R; Cavalca F; Bellosillo B; Benajiba L; Curto-Garcia N; Bellini M; Betti S; Harrison C; Rambaldi A; Vannucchi AM
Blood Cancer J; 2021 Feb; 11(2):21. PubMed ID: 33563901
[TBL] [Abstract][Full Text] [Related]
9. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Mascarenhas J; Heaney ML; Najfeld V; Hexner E; Abdel-Wahab O; Rampal R; Ravandi F; Petersen B; Roboz G; Feldman E; Podoltsev N; Douer D; Levine R; Tallman M; Hoffman R;
Leuk Res; 2012 Dec; 36(12):1500-4. PubMed ID: 22938832
[TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults.
Kucine N
Curr Hematol Malig Rep; 2020 Apr; 15(2):141-148. PubMed ID: 32172359
[TBL] [Abstract][Full Text] [Related]
11. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.
Tefferi A; Rumi E; Finazzi G; Gisslinger H; Vannucchi AM; Rodeghiero F; Randi ML; Vaidya R; Cazzola M; Rambaldi A; Gisslinger B; Pieri L; Ruggeri M; Bertozzi I; Sulai NH; Casetti I; Carobbio A; Jeryczynski G; Larson DR; Müllauer L; Pardanani A; Thiele J; Passamonti F; Barbui T
Leukemia; 2013 Sep; 27(9):1874-81. PubMed ID: 23739289
[TBL] [Abstract][Full Text] [Related]
12. How I treat myeloproliferative neoplasms in pregnancy.
Robinson S; Ragheb M; Harrison C
Blood; 2024 Feb; 143(9):777-785. PubMed ID: 38145575
[TBL] [Abstract][Full Text] [Related]
13. An "EZ" Epigenetic Road to Leukemia Stem Cell Metabolic Reprogramming?
Li M; Melnick AM
Cancer Discov; 2019 Sep; 9(9):1158-1160. PubMed ID: 31481404
[TBL] [Abstract][Full Text] [Related]
14. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
[TBL] [Abstract][Full Text] [Related]
15. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.
Yogarajah M; Tefferi A
Mayo Clin Proc; 2017 Jul; 92(7):1118-1128. PubMed ID: 28688466
[TBL] [Abstract][Full Text] [Related]
16. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms.
Ianotto JC; Couturier MA; Galinat H; Mottier D; Berthou C; Guillerm G; Lippert E; Delluc A
Int J Hematol; 2017 Oct; 106(4):517-521. PubMed ID: 28623609
[TBL] [Abstract][Full Text] [Related]
17. Imaging features of myeloproliferative neoplasms.
Murphy IG; Mitchell EL; Raso-Barnett L; Godfrey AL; Godfrey EM
Clin Radiol; 2017 Oct; 72(10):801-809. PubMed ID: 28615140
[TBL] [Abstract][Full Text] [Related]
18. Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms.
Huberty J; Eckert R; Gowin K; Mitchell J; Dueck AC; Ginos BF; Larkey L; Mesa R
Haematologica; 2017 Oct; 102(10):e384-e388. PubMed ID: 28596279
[No Abstract] [Full Text] [Related]
19. Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera.
Gangaraju R; Kim SJ; Dong JF; Swierczek S; Prchal JT
J Natl Compr Canc Netw; 2017 Jun; 15(6):757-760. PubMed ID: 28596255
[TBL] [Abstract][Full Text] [Related]
20. Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia: A Systematic Review.
Chu DK; Hillis CM; Leong DP; Anand SS; Siegal DM
Ann Intern Med; 2017 Aug; 167(3):170-180. PubMed ID: 28632284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
